SELLAS Life Sciences Group, Inc.

Healthcare · Biotechnology · United States

Last price 10.155 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.05B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli...